The role of biomarkers in the choice of therapy in breast cancer

  • Brigitte Mlineritsch
  • Sigrun Ressler
  • Richard Greil
short review


The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.


Breast cancer Biomarker Prognostic Predictive 


Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.


  1. 1.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.CrossRefPubMedGoogle Scholar
  3. 3.
    Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102.CrossRefPubMedGoogle Scholar
  8. 8.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.CrossRefPubMedGoogle Scholar
  10. 10.
    Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918.CrossRefPubMedGoogle Scholar
  11. 11.
    Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7.CrossRefGoogle Scholar
  12. 12.
    Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15.Google Scholar
  13. 13.
    Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72.CrossRefGoogle Scholar
  14. 14.
    Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62.CrossRefGoogle Scholar
  15. 15.
    Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69.PubMedGoogle Scholar
  16. 16.
    Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7.CrossRefGoogle Scholar
  17. 17.
    Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.CrossRefPubMedGoogle Scholar
  19. 19.
    Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823.CrossRefPubMedGoogle Scholar
  20. 20.
    Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988.CrossRefPubMedGoogle Scholar
  22. 22.
    Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74.CrossRefPubMedGoogle Scholar
  26. 26.
    Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011.Google Scholar
  27. 27.
    Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.CrossRefPubMedGoogle Scholar
  29. 29.
    Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157.Google Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Brigitte Mlineritsch
    • 1
  • Sigrun Ressler
    • 1
  • Richard Greil
    • 1
  1. 1.3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)Private Medical University Hospital SalzburgSalzburgAustria

Personalised recommendations